Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly ("Lilly") that the two parties ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...

Find out how developments in AlphaFold 3, alongside new predictive models, are changing approaches to drug discovery and ...

Southwest Research Institute scientists and engineers have developed a custom large language model (LLM) to accelerate drug design and discovery. Subscribe to our newsletter for the latest sci-tech ...

Computational drug discovery and design embodies the integration of advanced computational methods, machine learning, and cheminformatics to streamline the identification and optimisation of ...

Artificial intelligence has already made its mark in commercial industries, and there's a good argument to be made that AI is most impactful in the drug discovery marketplace: Drug discovery companies ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...